SecBot SecBot

IPHYF

Innate Pharma SA
OTC· Biological Products, (No Diagnostic Substances)· Inc. I0· CIK 0001598599 Biotech & Drug Discovery
$1.51 +0.00 (+0.00%)
Oct 23 4:00 PM ET · prev $1.51
1 year
−24.6%
from $2.00 · Oct 27
30 days
−8.5%
from $1.65
52-week range
$1.37–2.25
−33% from high · low Mar 23
Avg volume 20D
50
Oct 2 spike 1.0K
Short interest
2.8K
0.0%
Filing reports
10
analyzed by SecBot
SecBot read MIXED 5 reports · latest
Balance 1 bearish · 1 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 5/5
Strongest BEARISH Innate Pharma reported Q1 2026 revenue of €2.6M (up from €1.2M YoY) but disclosed a cash position of only…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • Short sellersSTEADY

    Short interest 0.0% to 2.8K shares.

  • TrendDOWNTREND

    6% below its 50-day average.

Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
May 19, 2026 SEC
Innate Pharma announced its executive team will participate in one-on-one investor meetings at the Jefferies Global…
6-K — Impact 2/10
May 13, 2026 SEC
Innate Pharma reported Q1 2026 revenue of €2.6M (up from €1.2M YoY) but disclosed a cash position of only €25.4M…
6-K — Impact 8/10
May 6, 2026 SEC
Innate Pharma filed a 6-K announcing a Q1 2026 business update conference call scheduled for May 13, 2026. The filing…
6-K — Impact 2/10

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current Q———$2.3M
Next Q———$2.3M
Current FY———$44.2M
Next FY———$107.4M

Short side

FINRA· Sep 30, 2026
2,774
shares short
0.0%
vs prior settlement
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Apr 29, 2026
Clinical Trial
IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma
Phase 2 · COMPLETED

SecBot reports

10 filings · 1 bullish · 2 bearish · 7 neutral
All IPHYF filing & press-release reports (10)